Pharmaceutical formulation for the treatment of nicotine dependence
US5643905A · kind A · utility
20Cited by
11References
7Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Oct 30, 1995 |
| Grant date | Jul 1, 1997 |
| Priority date | — |
| Expiry date | Oct 30, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/34
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to the use of galanthamine and the pharmaceutically acceptable acid addition salts thereof for the treatment of nicotine dependence. The active substances are released from pharmaceutical formulations, e.g., orally, transdermally, or otherwise parenterally in a continuous and controlled manner.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.